SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/07/14 Ziopharm Oncology Inc 10-Q 6/30/14 52:4.2M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 471K 2: EX-10.1 Material Contract HTML 127K 3: EX-31.1 Certification -- §302 - SOA'02 HTML 20K 4: EX-31.2 Certification -- §302 - SOA'02 HTML 20K 5: EX-32.1 Certification -- §906 - SOA'02 HTML 17K 34: R1 Document and Entity Information HTML 38K 24: R2 Balance Sheets HTML 102K 32: R3 Balance Sheets (Parenthetical) HTML 36K 36: R4 Statements of Operations HTML 45K 48: R5 Statement of Stockholders' Equity HTML 55K 25: R6 Statements of Cash Flows HTML 96K 31: R7 Business HTML 25K 22: R8 Summary of Significant Accounting Policies HTML 19K 16: R9 Recently Issued Accounting Pronouncements HTML 19K 49: R10 Restructuring HTML 23K 38: R11 Fair Value Measurements HTML 33K 37: R12 Net Loss per Share HTML 23K 42: R13 Related Party Transactions HTML 24K 43: R14 Commitments and Contingencies HTML 68K 41: R15 Warrants HTML 42K 44: R16 Common Stock HTML 19K 33: R17 Stock-Based Compensation HTML 50K 35: R18 Fair Value Measurements (Tables) HTML 29K 40: R19 Net Loss per Share (Tables) HTML 22K 52: R20 Warrants (Tables) HTML 44K 46: R21 Stock-Based Compensation (Tables) HTML 55K 27: R22 Business - Additional Information (Detail) HTML 19K 39: R23 Restructuring - Additional Information (Detail) HTML 40K 30: R24 Assets and Liabilities Measured at Fair Value on HTML 23K Recurring Basis (Detail) 14: R25 Potential Dilutive Shares Excluded from HTML 23K Computation of Diluted Net Loss Per Share (Detail) 47: R26 Related Party Transactions - Additional HTML 33K Information (Detail) 50: R27 Commitments and Contingencies - Additional HTML 248K Information (Detail) 19: R28 Number of Warrants Outstanding (Detail) HTML 20K 18: R29 Warrants - Additional Information (Detail) HTML 47K 20: R30 Assumptions Used In Binomial Valuation Model and HTML 26K Black-Scholes Valuation Model (Detail) 21: R31 Warrant Exercise (Detail) HTML 26K 23: R32 Common Stock - Additional Information (Detail) HTML 29K 13: R33 Stock-Based Compensation Expense on All Employee HTML 22K and Non-Employee Awards (Detail) 45: R34 Stock-Based Compensation - Additional Information HTML 39K (Detail) 26: R35 Fair Value of Stock Options Assumptions Using HTML 28K Black-Scholes Option Valuation Model (Detail) 28: R36 Stock Option Activity Under Stock Option Plan HTML 76K (Detail) 15: R37 Summary of Unvested Restricted Stock (Detail) HTML 41K 51: XML IDEA XML File -- Filing Summary XML 74K 12: EXCEL IDEA Workbook of Financial Reports XLSX 113K 17: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 506K 6: EX-101.INS XBRL Instance -- ziop-20140630 XML 767K 8: EX-101.CAL XBRL Calculations -- ziop-20140630_cal XML 104K 9: EX-101.DEF XBRL Definitions -- ziop-20140630_def XML 649K 10: EX-101.LAB XBRL Labels -- ziop-20140630_lab XML 931K 11: EX-101.PRE XBRL Presentations -- ziop-20140630_pre XML 721K 7: EX-101.SCH XBRL Schema -- ziop-20140630 XSD 136K 29: ZIP XBRL Zipped Folder -- 0001193125-14-300632-xbrl Zip 103K
EX-31.2 |
EXHIBIT 31.2
CERTIFICATION
I, Kevin G. Lafond, certify that:
1. I have reviewed this quarterly report on Form 10-Q of ZIOPHARM Oncology, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 7, 2014
/s/ Kevin G. Lafond |
Vice President, Chief Accounting Officer and Treasurer |
(Principal Financial and Accounting Officer) |
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 8/7/14 | 8-K | ||
For Period end: | 6/30/14 | |||
List all Filings |